These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 35024912)
1. Risk factors of persistent subretinal fluid after half-dose photodynamic therapy for treatment-naïve central serous chorioretinopathy. Li M; Qu J; Liang Z; Tang J; Hu J; Yao Y; Jin E; Li X; Zhao M Graefes Arch Clin Exp Ophthalmol; 2022 Jul; 260(7):2175-2182. PubMed ID: 35024912 [TBL] [Abstract][Full Text] [Related]
2. Subretinal fluid morphology in chronic central serous chorioretinopathy and its relationship to treatment: a retrospective analysis on PLACE trial data. Subhi Y; Bjerager J; Boon CJF; van Dijk EHC Acta Ophthalmol; 2022 Feb; 100(1):89-95. PubMed ID: 33998168 [TBL] [Abstract][Full Text] [Related]
3. Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes. Matušková V; Vysloužilová D; Uher M Semin Ophthalmol; 2018; 33(5):690-699. PubMed ID: 29252091 [TBL] [Abstract][Full Text] [Related]
4. OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY-GUIDED PHOTODYNAMIC THERAPY FOR ACUTE CENTRAL SEROUS CHORIORETINOPATHY. Hu J; Qu J; Li M; Sun G; Piao Z; Liang Z; Yao Y; Sadda S; Zhao M Retina; 2021 Jan; 41(1):189-198. PubMed ID: 32343102 [TBL] [Abstract][Full Text] [Related]
5. Microperimetric changes and fixation stability status after half-dose photodynamic therapy for chronic central serous chorioretinopathy. Gulkas S; Sahin O Eur J Ophthalmol; 2020 Sep; 30(5):1053-1060. PubMed ID: 31256613 [TBL] [Abstract][Full Text] [Related]
6. Photodynamic therapy in chronic central serous chorioretinopathy with subretinal fluid outside the fovea. van Dijk EHC; Dijkman G; Boon CJF Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):2029-2035. PubMed ID: 28674835 [TBL] [Abstract][Full Text] [Related]
7. CLINICAL FEATURES OF FLAT IRREGULAR PIGMENT EPITHELIAL DETACHMENT ASSOCIATED WITH CHOROIDAL NEOVASCULARIZATION IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY. Guo J; Tang W; Liu W; Chang Q; Xu G Retina; 2021 Jan; 41(1):199-207. PubMed ID: 32251241 [TBL] [Abstract][Full Text] [Related]
8. Isolated pigment epithelium detachment: evidence for relation to central serous chorioretinopathy and effect of photodynamic therapy. Arif F; Pryds A; Larsen M Acta Ophthalmol; 2018 Dec; 96(8):821-827. PubMed ID: 30246489 [TBL] [Abstract][Full Text] [Related]
9. Comparison of Retinochoroidal Vascular and Structural Changes after Half-Dose Photodynamic Therapy versus Half-Fluence Photodynamic Therapy Based on Optical Coherence Tomography Angiography in Eyes with Chronic Central Serous Chorioretinopathy. Karasu B; Akbas YB; Aykut A; Celebi ARC Ophthalmologica; 2022; 245(4):323-334. PubMed ID: 35249031 [TBL] [Abstract][Full Text] [Related]
10. Long-Term Outcomes of Full-Fluence and Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy. Son BK; Kim K; Kim ES; Yu SY Ophthalmologica; 2019; 241(2):105-115. PubMed ID: 30110697 [TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of chronic central serous chorioretinopathy after successful treatment with photodynamic therapy or micropulse laser. van Rijssen TJ; van Dijk EHC; Scholz P; Breukink MB; Dijkman G; Peters PJH; Tsonaka R; Keunen JEE; MacLaren RE; Hoyng CB; Downes SM; Fauser S; Boon CJF Acta Ophthalmol; 2021 Nov; 99(7):805-811. PubMed ID: 33565230 [TBL] [Abstract][Full Text] [Related]
12. Crossover to Half-Dose Photodynamic Therapy or Eplerenone in Chronic Central Serous Chorioretinopathy Patients. Feenstra HMA; van Dijk EHC; van Rijssen TJ; Tsonaka R; Diederen RMH; Schlingemann RO; Hoyng CB; Boon CJF Ophthalmol Retina; 2022 Oct; 6(10):930-938. PubMed ID: 35470085 [TBL] [Abstract][Full Text] [Related]
13. Comparison between the outcomes of fluorescein angiography-guided and indocyanine green angiography-guided half-time photodynamic therapy for central serous chorioretinopathy. Hayashida M; Miki A; Honda S; Nakamura M Photodiagnosis Photodyn Ther; 2020 Sep; 31():101955. PubMed ID: 32818640 [TBL] [Abstract][Full Text] [Related]
14. Choroidal Thickness Changes After Photodynamic Therapy and Recurrence of Chronic Central Serous Chorioretinopathy. Kim YK; Ryoo NK; Woo SJ; Park KH Am J Ophthalmol; 2015 Jul; 160(1):72-84.e1. PubMed ID: 25887629 [TBL] [Abstract][Full Text] [Related]
15. Comparing Half-Dose Photodynamic Therapy with Subthreshold Micropulse Laser for the Treatment of Central Serous Chorioretinopathy. Brelen ME; Ho M; Li S; Ng DSC; Yip YWY; Lee WS; Chen LJ; Young AL; Tham CC; Pang CP Ophthalmol Retina; 2024 May; 8(5):490-498. PubMed ID: 37956794 [TBL] [Abstract][Full Text] [Related]
16. Half-dose photodynamic therapy versus 577 nm subthreshold pulse laser therapy in treatment-naive patients with central serous chorioretinopathy. Sitnilska V; Schiller P; Krohne TU; Altay L BMC Ophthalmol; 2024 Jan; 24(1):8. PubMed ID: 38178104 [TBL] [Abstract][Full Text] [Related]
17. FLAT IRREGULAR PIGMENT EPITHELIUM DETACHMENT IN CENTRAL SEROUS CHORIORETINOPATHY: A Form of Pachychoroid Neovasculopathy? Hwang H; Kim JY; Kim KT; Chae JB; Kim DY Retina; 2020 Sep; 40(9):1724-1733. PubMed ID: 31584559 [TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy. van Rijssen TJ; van Dijk EHC; Dijkman G; Boon CJF Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1395-1402. PubMed ID: 29732468 [TBL] [Abstract][Full Text] [Related]
20. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY. Cheng CK; Chang CK; Peng CH Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]